Key Takeaways
- Revenue grew 19% YoY, but H1 is flat: Consolidated revenue hit INR398 crores, yet standalone was flat YoY as demand shifts to H2. Management guided FY24 at 20–25% growth, with a sharper number promised by end-Q2.
- The order book is the story: LOIs and contracts worth INR7,669 crores provide strong visibility, with peak annual revenue of ~INR1,700 crores expected over 5–7 years. A INR3,686 crore contract with a Japanese multinational headlined the quarter.
- Margins held at 29% in a deflationary world: The cost-plus, contract-based model passed through all input costs, keeping EBITDA inside the long-term band. Management expects a consistent 26–28% band going forward.
- Fluorination and flow chemistry are the moat: In-house technology, a deep fluoro supply chain from HF/KF to advanced intermediates, and a move from batch to flow chemistry underpin the right to win. One molecule is nearing global-first flow commercialization.
- What to watch next quarter: The sharper FY24 growth number promised by end-Q2, the pace of LOI revenue conversion (targeting INR300 crores this year), and progress on the 3xper Innoventure pharma collaboration.
Order Book & Revenue Visibility
- LOI stock stands at INR7,669 crores: This includes a INR3,686 crore contract with a Japanese multinational and an LOI with an American multinational for fluorinated products, both signed in Q1. The book provides multiyear visibility.
- Revenue conversion is back-end loaded: LOIs contributed INR100 crores in FY23 and are expected to add INR200 crores more this year for a total of INR300 crores. A large part of the Q1 signings will start contributing from calendar year 2025 onward.
- Peak revenue math: The INR7,700 crore order book is expected to generate peak annual revenue of ~INR1,700 crores, ramping over 5–7 years, with some products reaching full run-rate in 3 years and others in 4. Over the next 3 years, LOI revenue should approach a four-digit number.
- The base business is holding: Despite global agrochemical weakness and inventory liquidation, the contractual nature of demand kept the standalone business stable. Exports contributed 61% of revenue, and the top 10 customers accounted for ~90% of the total.
- H1 is a waiting game: The first two quarters are looking flattish, with incremental demand shifting to the second half. Revenue scheduling from LOIs has not materially changed from prior projections, though individual molecules can shift by a quarter.
Thakkar: "I think we should be looking at 20%, 25% of growth rate. More sharper number probably I can give you by the end of the second quarter."
Margin Structure & Cost Pass-Through
- EBITDA margin held at 29%: This sits above the guided 26–28% long-term band, aided by the cost-plus model that passes through raw materials, overheads, utility and energy costs across most of the portfolio.
- Gross margin moves with product mix: Management runs the business on EBITDA, not gross margin. Products with less complexity carry lower overheads and a different RM contribution, so quarterly gross margin swings reflect the portfolio mix rather than a structural shift.
- RM price swings are muted: Raw materials are ~40% of revenue, and that share is even lower for new-age molecules. Multiyear contracts mean deflationary environments can cause some price movement, but the aggregate top-line impact is not significant.
- Inventory is held by design: Vendors do not offer forward contracts, so inventory must be bought and held across RM, WIP and finished goods. Customers insist on particular FG inventory levels where Anupam is the primary or single supplier, tying up working capital but securing supply.
- Working capital is unwinding: Net working capital has dropped from INR290 crores to INR250 crores, then INR220 crores, INR200 crores, and is expected to go sub-INR200 crores over the next few years as cautionary inventory from FY22-end unwinds.
Thakkar: "if you see our EBITDA margins will be fairly in a consistent band of around 26% to 28%, maybe a little higher probably in a quarter or two, but on an average, you will see that kind of a number."
Technology Moat & Right to Win
- In-house technology, not tech-packs: Anupam does not take technology packages from customers. Most products and technology are developed internally, which management credits to the R&D team's capability.
- The fluorination edge: The right to win rests on three pillars: (1) multiple in-house chemistries including fluorination, nitration and hydrolysis; (2) a deep, integrated supply chain from HF and KF through to key starting materials and N-2/N-1 intermediates; (3) process optimization expertise that moves molecules from batch to continuous to flow chemistry, driving down the cost curve.
- Flow chemistry milestone approaching: Anupam is in the final stage of commercializing a new-age molecule using flow chemistry and claims it will be the first company globally to launch this molecule via that route. One fluorinated product was already commercialized in the quarter.
- Tanfac integration deepens: HF and KF supplies from Tanfac have begun and will ramp up as the fluorination portfolio expands. Anupam holds a right of first refusal if TIDCO decides to offer its Tanfac stake.
Thakkar: "The answer is that we don't take tech-packs from a customer and most of our products and technology is in-house and thanks to our RM team that they have been able to deliver these kinds of products."
Pharma & New Business Development
- Two new fluorinated pharma molecules launched: These are part of a pipeline of 10-plus new molecules planned for commercialization in FY24, all in-house and fluorinated. Total products now stand at 55.
- The pharma strategy is two-pronged: First, target products not manufactured in India that are imported in reasonable quantity and high value, where Anupam's fluoro-based key starting materials overlap with its agro/polymer value chain. Second, split revenue 30–40% domestic and the rest export, with a business model similar to agro and polymers.
- 3xper Innoventure MOU is early-stage: This is a knowledge-sharing collaboration, not a joint venture, with no corporate entity being formed. Business will run primarily from Anupam with support from Mr. Govindarajan. Sales will be direct, not through the MOU vehicle. Numbers and timelines are not yet crystallized.
- Geographic expansion is working: New business development teams in Japan, the U.S. and Europe have shortened cycle times and delivered two niche high-end molecules. The U.S. LOI is expected to significantly increase the Americas revenue share.
- No new capex needed for pharma: The pharma molecules being discussed are covered by capex already incurred. The INR670 crore capex balance, to be invested over the next 12 months, can service a large part of the LOIs, with no further debt required.
Thakkar: "Give us a little bit more time to frame that before we come to you and give you a guidance or a more formal view on this because it's right now an MOU, and that will be converted into a more formal relationship as we go forward."
Capex, Returns & Balance Sheet
- INR670 crores capex, no new debt: The remaining capex will be invested over the next 12 months and can be funded entirely from internal cash generation. Cash flow will naturally unwind existing debt.
- LOIs fit within existing capex: A large part of the LOI portfolio can be serviced from the INR670 crore program. For products targeting FY28 or FY29, additional capex may be needed, but the multipurpose plant design makes capacity sizing fungible across molecules.
- Asset turns and ROCE are improving: More brownfield expansion means better asset turns. Management assured ROCE will improve further but declined to put a public number on the hurdle rate, saying only it would be better than whatever the analyst is thinking.
- Working capital intensity is falling: Net working capital has already dropped from INR290 crores to INR250 crores and is on a trajectory toward sub-INR200 crores. Management declined to disclose the exact Q1 inventory figure, citing that balance sheet numbers are not discussed quarterly.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| FY24 revenue growth | 20–25% growth rate | Sharper number by end-Q2 FY24 |
| LOI revenue contribution | INR300 crores total in FY24 (INR200 crores addition) | FY24 |
| LOI peak revenue | ~INR1,700 crores annually from INR7,700 crore order book | Over 5–7 years |
| Long-term revenue CAGR | 25% plus or minus | Long-term basis |
| EBITDA margin band | 26–28%, maybe higher in a quarter or two | Ongoing |
| Capex deployment | Balance INR670 crores invested | Next 12 months |
| Net working capital | Drop to sub-INR200 crores | Over next few years |
| New molecule launches | 10-plus molecules commercialized | FY24 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Consolidated revenue | ₹398 cr, +19% YoY |
| EBITDA margin | 29%, maintained within long-term band despite deflationary environment |
| Revenue growth guidance (FY24) | 20% to 25%, with first half flattish and demand shifting to second half |
| Order book (LOIs and contracts) | ₹7,669 cr as of June 30, 2023, providing multi-year revenue visibility |
| LOIs signed during the quarter | ₹4,066 cr, including a ₹3,686 cr contract with a Japanese multinational |
| Life Sciences segment revenue | ₹255 cr, vs ₹290 cr in Q1 FY23; contributed 90% of total revenue |
| Other Specialty Chemicals segment revenue | ₹28 cr, vs ₹14 cr in Q1 FY23 |
| Exports share | 61% of total revenue |
| Top 10 customer concentration | 90% of total revenue, across 24 products |
| Total commercialized products | 55, including 2 new fluorinated pharma molecules launched in Q1 FY24 |
| Total customers | 73, of which 29 are multinationals |
| Capex spent till end of Q1 FY24 | ₹124.4 cr out of planned ₹670 cr; balance to be invested in next 12 months |
| Revenue from LOIs and contracts | ~₹100 cr in FY23, expected to ramp to ~₹300 cr in FY24 |
| ROCE | 15% in the last year |
| Net working capital trajectory | Dropping from ₹290 cr to ₹250 cr, then to ₹220 cr, to ₹200 cr and sub-₹200 cr over next few years |